SCHEMBL9975964

SCHEMBL9975964

COc1cc(/C=C/c2cc(=O)c3ccccc3o2)cc(OC)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.68
ALDH1A1 P00352 5/20 0.68
HPGD P15428 5/20 0.68
KDM4E B2RXH2 4/20 0.68
SMN1; SMN2 Q16637 4/20 0.68
NPC1 O15118 4/20 0.68
RAB9A P51151 4/20 0.68
NPSR1 Q6W5P4 1/20 0.68
MAOA P21397 3/20 0.57
MAOB P27338 2/20 0.57
TP53 P04637 3/20 0.53
CYP3A4 P08684 2/20 0.53
HSD17B10 Q99714 2/20 0.52
TNKS O95271 2/20 0.52
LMNA P02545 1/20 0.52
GLA P06280 1/20 0.52
THRB P10828 1/20 0.52
KCNA5 P22460 1/20 0.52
KCNH2 Q12809 1/20 0.52
NLRP3 Q96P20 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9975963 0.90 KDM4E (0.68) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL9975962 0.89 MAPT (0.80) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL9976042 0.84 KDM4E (0.64) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL11823788 0.82 KDM4E (0.64) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL9975959 0.82 KDM4E (0.64) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL435366 0.81 HPGD (1.00) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL2465240 0.81 HPGD (1.00) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL28245558 0.77 KDM4E (0.74) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL9976005 0.76 KDM4E (0.78) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL9975965 0.76 KDM4E (0.78) MAPTALDH1A1HPGDKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
WO-2012087889-A2 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-28 WO disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157465-A1 DNA METHYLATION INHIBITORS MECP2, DNMT1, DNMT3B MAPT 3677/4885ALDH1A1 2789/4885HPGD 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.